Trailing Twelve Months Sales Growth: ProKidney Corp. (PROK)

Graphic logo of ProKidney Pharma (PROK)

Can strong talent in kidney regeneration drive growth for ProKidney Corp. (PROK)? High confidence in cellular innovations and the TTM year-over-year sales growth trajectory confirm the potential. The value of 4.30 shows the most recent figure for this metric. Business prospects rely on the success of the REACT system, which offers an alternative to transplantation, attracting new investors.

PROK - ProKidney Corp. Sales Growth YoY (Last Twelve Months) over the range 02/11/2024 - 11/17/2026

ProKidney Corp (PROK) - metric breakdowns and financial figures

- market value and analyst target forecast:
- company stock exchange capitalization indicators:
Summary company analytics:ProKidney Pharma - PROK
Original product of ProKidney

Year-over-year sales growth (TTM) measures the relative change in revenue over the last twelve months, allowing investors to identify the moment of operational turnaround and assess business scaling dynamics. For ProKidney Corp. (PROK), which attracts top cell therapy specialists, the annual sales volume trend (LTM) serves as an indicator of innovation commercialization, determining the company's fundamental value through the lens of its ability to monetize unique scientific capital.